Enlightenment through smart measurements

Open menu

News & Events

OpSens Announces FDA Clearance for the SavvyWire™ for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

15 September 2022

OpSens Announces FDA Clearance for the SavvyWire™ for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures Quebec City, Quebec, September 15, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received 510(k) regulatory clearance from…

Read more

Opsens Solutions will be present at ESREF 2022, in Berlin (Germany) from September 26-29, 2022

9 September 2022

Opsens Solutions will be present at ESREF 2022, in Berlin (Germany) from September 26-29, 2022 at the H4 Hotel Berlin Alexanderplatz, Please come to visit us at booth 2.

OpSens to Host Third Quarter Fiscal Year 2022 Financial Results Conference Call on Thursday, July 14

7 July 2022

OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JULY 14 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, July 7, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, will…

Read more

OpSens Announces Second Quarter Fiscal 2022 Financial Results

13 April 2022

OpSens Announces Second Quarter Fiscal 2022 Financial Results Conference call will be held today at 11:00 a.m. ET   Quebec City, Quebec, April 13, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today released results for its…

Read more

OpSens Appoints Brad Davis as New Chief Commercial Officer

9 February 2022

OpSens Appoints Brad Davis as New Chief Commercial Officer Davis to lead global commercialization as OpSens pursues transformational growth Quebec City, Quebec, February 9, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Brad Davis will assume…

Read more

OpSens Named to 2022 OTCQX Best 50

24 January 2022

OPSENS Named to 2022 OTCQX Best 50   Quebec City, Quebec, January 24, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce it has been named to the 2022 OTCQX® Best 50, a ranking of top…

Read more

OpSens Announces First Quarter Fiscal 2022 Financial Results

13 January 2022

OpSens Announces First Quarter Fiscal 2022 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, January 13, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the first quarter…

Read more

OpSens to Host First Quarter FY 2022 Financial Results Conference Call on Thursday, January 13, 2022

6 January 2022

OPSENS TO HOST FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JANUARY 13, 2022  Conference call to be conducted at 11:00 am ET Quebec City, Quebec, January 6, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology,…

Read more

OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure

13 December 2021

OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure Quebec City, Quebec, December 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submission with the U.S….

Read more

OpSens to Present at the Lytham Partners Winter 2021 Investor Conference Presentation at 11 AM (ET), Monday December 13, 2021

7 December 2021

OPSENS TO PRESENT AT THE LYTHAM PARTNERS WINTER 2021 INVESTOR CONFERENCE Presentation at 11 AM (ET), Monday December 13, 2021   Quebec, Quebec, December 7, 2021 – OpSens inc. («OpSens» or the «Company») (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be…

Read more